



下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEL-165041Cat. No.: HY-20019CAS No.: 79558-09-1分式: CHO分量: 402.44作靶點(diǎn): PPAR作通路: Cell Cycle/DNA Damage儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (124.24 mM; Need ultrasonic)H2O : 4
2、0% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (6.21 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (6.21 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 L-165041種細(xì)胞滲透的 PPAR 激動(dòng)劑,對(duì) PPAR 和 PPAR 的 Ki 值分別為 6 nM 和 約 730 nM,可以在
3、 NIH-PPAR 細(xì)胞中誘導(dǎo)脂肪細(xì)胞分化。IC50 & Target PPAR PPAR6 nM (Ki) 730 nM (Ki)體外研究 L-165041 is a PPAR agonist, with Kis of 6 nM and appr 730 nM for PPAR and PPAR, respectively 1. L-165041 (1 or 5M) inhibits VEGF-induced endothelial cells (ECs) proliferation and migration. L-165041negatively affects cell cycle p
4、rogression in VEGF-activated human umbilical vein ECs (HUVECs). L-165041(10M)inhibits PPAR-independent, VEGF-induced angiogenesis 2. PPAR ligand L-165041 inhibitsPDGF-induced rVSMC proliferation and migration. With 1 h of L-165041 pretreatment, PDGF-inducedcellular migration is inhibited. L-165041 (
5、10 M) significantly suppresses S phase transition induced byPDGF 4.體內(nèi)研究 L-165041 (5 mg/kg/day, i.p.) significantly lowers the formation of lipid droplets in mice. L-165041 markedlyreduces the level of both the hepatic cholesterol and triglycerides in mice. L-165041 increases mRNAexpression levels of
6、 PPAR compared to the vehicle group. Lipoprotein lipase (LPL) expression in L-165041-treated mice is significantly higher than that in the vehicle group 3.PROTOCOLCell Assay 2 Human umbilical vein ECs (HUVECs) are cultured in EGM-2. Subconfluent HUVECs are made quiescent byserum starvation EBM-2 con
7、taining 0.1% fetal bovine serum (FBS) for 4h. The cells are pretreated with thePPAR ligand L-165041 or GW501516 for 6h followed by VEGF (10ng/mL) induction 2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal LDLR/ mice are divided into vehicle (0.1
8、 N NaOH) and L-165041 (5 mg/kg/day) group (9 animals in eachAdministration 3 group). LDLR/ mice receive either NaOH or L-165041 via daily intraperitoneal injection (i.p.) for 16 weekswith the Western diet. Body weight is measured once a week and the blood samples for a serum parameteranalysis are co
9、llected using an eye-bleeding method every 4 weeks. At the end of the experiment, LDLR/mice are fasted for 24 h before sacrificed and the liver samples are either fixed in formalin or frozen at 70Cfor further analysis. All animals are housed in polycarbonate cages in a room with a 12-h light/12-h da
10、rkcycle, and maintained at a constant temperature of 22C 3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Berger J, et al. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biologicaleffec
11、ts. J Biol Chem. 1999 Mar 5;274(10):6718-25.2. Park, Jin-Hee., et al. The PPAR ligand L-165041 inhibits vegf-induced angiogenesis, but the antiangiogenic effect is not related toPPAR. Journal of Cellular Biochemistry (2012), 113(6), 1947-1954.3. Lim, Hyun-Joung., et al. PPAR ligand L-165041 ameliora
12、tes Western diet-induced hepatic lipid accumulation and inflammation in2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemELDLR-/- mice. European Journal of Pharmacology (2009), 622(1-3), 45-51.4. Lim, Hyun-Joung., et al. PPAR agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cellcycle. Atherosclerosis (Amsterdam, Netherlands) (2009), 202(2), 446-454.McePdfHeightCauti
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 寵物藥固體片劑項(xiàng)目可行性研究報(bào)告(參考)
- 軟件測(cè)試中的思維方式2025年試題及答案
- 如何高效備戰(zhàn)2025年計(jì)算機(jī)二級(jí)VFP考試試題及答案
- 2025年計(jì)算機(jī)ACCESS考試模擬考題試題及答案
- 2025年VFP考試全方位技巧試題及答案
- 良好習(xí)慣養(yǎng)成ACCESS試題及答案
- 使用GDB調(diào)試的技巧試題及答案
- 理解C語(yǔ)言并行編程試題及答案
- 計(jì)算機(jī)二級(jí)VFP考試新穎試題及答案
- 能源系統(tǒng)軟件測(cè)試中的特殊要求與策略試題及答案
- 湯圓產(chǎn)品HACCP計(jì)劃
- 教材選題申報(bào)表
- 防汛物資臺(tái)賬參考模板范本
- 瀝青路面施工旁站監(jiān)理記錄表多篇
- 派出所轄區(qū)治安形勢(shì)分析報(bào)告(通用6篇)
- DN900鋼管dn800PE管定向鉆穿越京杭大運(yùn)河施工方案
- 養(yǎng)老地產(chǎn)項(xiàng)目區(qū)域綜合開(kāi)發(fā)新模式_secret
- 員工手冊(cè)070509
- 羅斯公司理財(cái)Chap004全英文題庫(kù)及答案
- 工業(yè)固體廢物綜合利用項(xiàng)目建議書(shū)范文
- 雍布拉康課件
評(píng)論
0/150
提交評(píng)論